CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 integrins

Neoplasia

Volumn 8, Issue 4, 2006, Pages 290-301

  Engl, Tobias ^a   Relja, Borna ^a   Marian, Dana ^a   Blumenberg, Christa ^a   Müller, Iris ^a   Beecken, Wolf Dietrich ^a   Jones, Jon ^a   Ringel, Eva M ^a   Bereiter Hahny, Jürgen ^a   Jonas, Dietger ^a   Blaheta, Roman A ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Adhesion; CXCL12; CXCR4; Integrins; Prostate carcinoma cells

Indexed keywords

ALPHA3 INTEGRIN; ALPHA5 INTEGRIN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; FIBRONECTIN; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE P38; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 33646422999     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05694     Document Type: Article

References (37)

1. Arya M, Patel HR, McGurk C, Tatoud R, Klocker H, Masters J, and Williamson M (2004). The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 4, 291-303.
2. Singh S, Singh UP, Grizzle WE, and Lillard JW Jr (2004). CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 84, 1666-1676.
3. Hart CA, Brown M, Bagley S, Sharrard M, and Clarke NW (2005). Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer 92, 503-512.
4. Vaday GG, Hua SB, Peehl DM, Pauling MH, Lin YH, Zhu L, Lawrence DM, Foda HD, and Zucker S (2004). CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res 10, 5630-5639.
5. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, et al. (2004). Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18, 1240-1242.
6. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, and McCauley LK (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62, 1832-1837.
7. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, and Taichman RS (2003). Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89, 462-473.
8. Wittig BM, Thees R, Kaulen H, Gott K, Bartnik E, Schmitt C, Meyer zum Buschenfelde KH, and Dippold W (1996). Alpha(1,3)fucosyltransferase expression in E-selectin-mediated binding of gastrointestinal tumor cells. Int J Cancer 67, 80-85.
9. Blaheta RA, Hailer NP, Brude N, Wittig B, Leckel K, Oppermann E, Bachmann M, Harder S, Cinatl J, Scholz M, et al. (2000). In vitro analysis of verapamil-induced immunosuppression: potent inhibition of T cell motility and lymphocytic transmigration through allogeneic endothelial cells. Transplantation 69, 588-597.
10. Melchionna R, Porcelli D, Mangoni A, Carlini D, Liuzzo G, Spinetti G, Antonini A, Capogrossi MC, and Napolitano M (2005). Laminar shear stress inhibits CXCR4 expression on endothelial cells: functional consequences for atherogenesis. FASEB J 19, 629-631.
11. Salmaggi A, Gelati M, Pollo B, Frigerio S, Eoli M, Silvani A, Broggi G, Ciusani E, Croci D, Boiardi A, et al. (2004). CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells. J Neuro-Oncol 67, 305-31 7.
12. Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, et al. (2005). Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65, 5864-5871.
13. Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, Mantovani A, and Allavena P (2004). Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 64, 8420-8427.
14. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, and Weinberg RA (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
15. Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T, and Schettini G (2005). Stromal cell-derived factor-1 alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 308, 241-253.
16. Hartmann TN, Burger JA, Glodek A, Fujii N, and Burger M (2005). CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24, 4462-4471.
17. Samara GJ, Lawrence DM, Chiarelli CJ, Valentino MD, Lyubsky S, Zucker S, and Vaday GG (2004). CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 214, 231-241.
18. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, and Hoon DS (2005). Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23, 2744-2753.
19. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, and Castello G (2005). Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11, 1835-1841.
20. Mochizuki H, Matsubara A, Teishima J, Mutaguchi K, Yasumoto H, Dahiya R, Usui T, and Kamiya K (2004). Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun 320, 656-663.
21. 3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59, 1655-1664.
22. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, and Trikha M (2003). Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 20, 413-420.
23. Shen X and Falzon M (2003). Parathyroid hormone-related protein upregulates integrin expression via an intracrine pathway in PC-3 prostate cancer cells. Regul Pept 113, 17-29.
24. Cardones AR, Murakami T, and Hwang ST (2003). CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res 63, 6751-6757.
25. + stem/progenitor cells to bone marrow. Blood 103, 2981-2989.
26. Leroy-Dudal J, Demeilliers C, Gallet O, Pauthe E, Dutoit S, Agniel R, Gauduchon P, and Carreiras F (2005). Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer 114, 531-543.
27. Sun Y, Cheng Z, Ma L, and Pei G (2002). Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem 277, 49212-49219.
28. Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, Qin S, Newman W, and Groopman JE (1998). The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 273, 23169-23175.
29. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, and Kazanietz MG (2003). Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 278, 33753-33762.
30. Edlund S, Bu S, Schuster N, Aspenstrom P, Heuchel R, Heldin NE, ten Dijke P, Heldin CH, and Landstrom M (2003). Transforming growth factorbeta 1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 14, 529-544.
31. Chen L, He HY, Li HM, Zheng J, Heng WJ, You JF, and Fang WG (2004). ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 215, 239-247.
32. Hayes SA, Huang X, Kambhampati S, Platanias LC, and Bergan RC (2003). p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 22, 4841-4850.
33. Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC, and Bergan RC (2005). Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65, 3470-3478.
34. Aguirre-Ghiso JA, Estrada Y, Liu D, and Ossowski L (2003). ERK (MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63, 1684-1695.
35. Bulavin DV and Fornace AJ Jr (2004). p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92, 95-118.
36. Dasgupta P, Betts V, Rastogi S, Joshi B, Morris M, Brennan B, Ordonez-Ercan D, and Chellappan S (2004). Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein: novel links between apoptotic signaling and cell cycle machinery. J Biol Chem 279, 38762-38769.
37. Khaled AR, Bulavin DV, Kittipatarin C, Li WQ, Alvarez M, Kim K, Young HA, Fornace AJ, and Durum SK (2005). Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol 169, 755-763.